We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.
Candidate NameCand | PreclinicalPre | Phase 1Ph 1 | Phase 2Ph 2 | Phase 3Ph 3 | CollaboratorsCollab |
|---|---|---|---|---|---|
ZN-c3: Wee1 Inhibitor  | | ||||
| Monotherapy | |||||
ZN-c3: Wee1 InhibitorUterine Serous Carcinoma* | |||||
Biomarker-Driven* | |||||
Solid Tumors | |||||
| Combination | |||||
ZN-c3: Wee1 InhibitorOsteosarcoma (+ gemcitabine)* | |||||
Ovarian Cancer (+ niraparib) | |||||
Ovarian Cancer (+ chemo) | |||||
ZN-d5: BCL-2 Inhibitor  | | ||||
| Monotherapy | |||||
ZN-d5: BCL-2 InhibitorAL Amyloidosis* | |||||
AML + Non-Hodgkin’s Lymphoma | |||||
| Combination | |||||
ZN-d5: BCL-2 Inhibitor | |||||
ZN-c5: Oral SERD1 | | ||||
| Monotherapy | |||||
ZN-c5: Oral SERD1Breast Cancer | |||||
ZN-e4: EGFR Inhibitor1  | | ||||
| Monotherapy | |||||
ZN-e4: EGFR Inhibitor1NSCLC | |||||
BCL-xL Degrader | |||||
| Monotherapy | |||||
BCL-xL Degrader | |||||
+ Registrational trial with FDA Fast Track designation
* Potentially registrational trial
1 Zentalis will discontinue the clinical development of ZN-c5 and ZN-e4 following completion of its existing clinical trials, which are closed to accrual, in these two programs.